Maze Therapeutics rises as kidney disease drug shows positive results in trial

Maze Therapeutics

25/03/2026 11:15

** Shares of biotech firm Maze Therapeutics MAZE.O rise 3.1% to $50.50 premarket

** Co says its experimental drug MZE829 reduced protein in urine, a key sign of kidney damage, in a mid‑stage study

** Drug targets APOL1‑mediated kidney disease, an inherited kidney condition that can lead to kidney failure

** Study showed an average 35.6% drop in urine protein after 12 weeks; about half of patients saw drops of over 30%, co says

** Adds larger reductions were seen in patients with a severe kidney scarring condition and those without diabetes

** Co says it plans a larger, late‑stage study of MZE829 following the results

** As of last close, stock was up ~18% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))